Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GS-7340 Clear all
Completed Phase 1 Interventional

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

NCT01671787
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
GS-7340, Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 3 Interventional Results available

Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

NCT01003990
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Atazanavir/Ritonavir, Tenofovir/Emtricitabine, Lopinavir/ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK Multi-dose Study of TAF/EVG Vaginal Insert

NCT06087913
View directory record Official record
Conditions
Safety Issues
Interventions
TAF/EVG vaginal insert, Matching Placebo vaginal insert
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 1 Interventional

Raltegravir as Early Therapy in African-Americans Living With HIV Study

NCT00667433
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir + Truvada
Drug
Lead sponsor
David A Wohl, MD
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 12, 2026, 5:18 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

NCT05630755
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 12, 2026, 5:18 PM EDT
Enrolling by invitation Phase 2 Interventional

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

NCT05957913
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Truvada (tenofovir/emtricitabine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 12, 2026, 5:18 PM EDT
Recruiting Not applicable Interventional

WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women

NCT06656676
View directory record Official record
Conditions
HIV Prevention
Interventions
WePrEP: A shared decision-making tool, Active comparator: CDC recommendations for discussing PrEP
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sheridan, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Optimization of a Tenofovir Enema for HIV Prevention

NCT02750540
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir enema, Saline enema
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

NCT04585737
View directory record Official record
Conditions
HIV I Infection
Interventions
Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
Drug
Lead sponsor
Charlotte-Paige Rolle, MD
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 12, 2026, 5:18 PM EDT
Terminated Phase 2 Interventional Results available

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

NCT02452528
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

NCT00350272
View directory record Official record
Conditions
HIV Infections
Interventions
Elvucitabine, Lamivudine, Tenofovir, Efavirenz
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 1 Interventional

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

NCT00660972
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 12, 2026, 5:18 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The HOPE Study: Characterizing Patients With Hepatitis B and C

NCT02995252
View directory record Official record
Conditions
Hepatitis B， Chronic, Hepatitis C
Interventions
Blood draws, Tenofovir Alafenamide, Knowledge Index Questionnaire, Liver transient elastography (FibroScan), Liver Biopsy
Other · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 99 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2034
U.S. locations
2
States / cities
Baltimore, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 12, 2026, 5:18 PM EDT
Active, not recruiting Phase 4 Interventional

Accelerated ART Initiation for PWHIV Who Are Out of Care

NCT06374758
View directory record Official record
Conditions
HIV Infections, ART, Noncompliance, Patient
Interventions
The Accelerate model of care, bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Columbia, Missouri • Kansas City, Missouri • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 12, 2026, 5:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

NCT03789968
View directory record Official record
Conditions
HIV/AIDS
Interventions
bictegravir/emtricitabine/tenofovir alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT01106586
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Stribild, ATV, Ritonavir, FTC/TDF, Stribild Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
86
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 12, 2026, 5:18 PM EDT
Recruiting Not applicable Interventional

Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial

NCT07125235
View directory record Official record
Conditions
Behavioral Intervention, Viral Suppression of HIV Infection, ART Adherence
Interventions
reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention, urine tenofovir point-of-care self-test
Behavioral · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 4 Interventional

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

NCT00224445
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Atazanavir, Ritonavir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

NCT02831673
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

NCT03197961
View directory record Official record
Conditions
HIV/AIDS, Contraception
Interventions
tenofovir/emtricitabine, DMPA
Combination Product · Drug
Lead sponsor
Sharon Achilles
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 12, 2026, 5:18 PM EDT
Completed No phase listed Observational Results available

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

NCT01456962
View directory record Official record
Conditions
Women's Health, HIV Infection, Genital Diseases, Female
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 12, 2026, 5:18 PM EDT
Completed No phase listed Observational

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

NCT04301661
View directory record Official record
Conditions
HIV-1-infection
Interventions
Blood collection, Abacavir/lamivudine, Tenofovir alafenamide/emtricitabine, Switch
Other · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Sep 12, 2026, 5:18 PM EDT
Completed No phase listed Observational

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

NCT03646370
View directory record Official record
Conditions
HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases, Weight Gain, Renal Function Abnormal, Hyperglycemia
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 12, 2026, 5:18 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
38
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 12, 2026, 5:18 PM EDT